Dr. John Burke to present at QSP Congress Boston 2015

Dr. John Burke, Co-Founder, President, and CEO of Applied Biomath, will present "QSP approaches enabling quantitative decisions in drug discovery from early research to clinical trials" at QSP Congress Boston 2015.

Following are the key focal points of Dr. Burke's presentation:

QSP approaches have been used successfully in Pharma and Biotechs to drive quantitative decisions to reduce late stage attrition, and accelerate best-in-class therapeutics to meet unmet medical need

Here we show several case studies where these approaches have driven quantitative decisions resulting in savings of millions of dollars and shortening timelines

Finally, we will highlight several challenges and opportunities in the QSP field in the short and long term

Dr. Burke’s BS and MS are in Applied Mathematics from the University of Massachusetts, Lowell, in 1993 and 1995, respectively. His PhD degree is in Applied Mathematics from Arizona State University in 2003. His research interests include singularly and randomly perturbed differential equations, bifurcation theory, and applying dynamical systems theory to study and understand how cells and tissues make decisions in humans, and human disease. Prior to co-founding Applied BioMath, Dr. Burke joined Boehringer Ingelheim in 2008 as Associate Director, Head of Systems Biology. In 2011, he was promoted to Senior Principal Scientist. At Boehringer Ingelheim, he started, developed and managed the Systems Biology group, portfolio, and strategy. The group was responsible for applying systems techniques to the drug discovery process across all Research sites, and supporting Development and Medicine. Prior to Boehringer Ingelheim, Dr. Burke was at Merrimack Pharmaceuticals, Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, HMS, and was a Sr. Postdoctoral Fellow in Douglas A. Lauffenburger’s lab, Biological Engineering Department, MIT. While at MIT and HMS, Dr. Burke provided consulting or advising for various companies, including AstraZeneca, Pfizer, Momenta, Matlab, and RES Group. Presently he is an on the advisory boards for the MIT “Human Physiome on a Chip” MIT-DARPA Program, and the Mathematics Department at the University of Massachusetts, Lowell.